CY1119483T1 - Θεραπευτικος παραγων για τις αγχωδεις διαταραχες - Google Patents

Θεραπευτικος παραγων για τις αγχωδεις διαταραχες

Info

Publication number
CY1119483T1
CY1119483T1 CY20171101029T CY171101029T CY1119483T1 CY 1119483 T1 CY1119483 T1 CY 1119483T1 CY 20171101029 T CY20171101029 T CY 20171101029T CY 171101029 T CY171101029 T CY 171101029T CY 1119483 T1 CY1119483 T1 CY 1119483T1
Authority
CY
Cyprus
Prior art keywords
party
therapeutic
anxiety disorders
prophylaxis
pyridyl
Prior art date
Application number
CY20171101029T
Other languages
English (en)
Inventor
Junya Kase
Tomoyuki Kanda
Original Assignee
Kyowa Hakko Kirin Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43649340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119483(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co., Ltd. filed Critical Kyowa Hakko Kirin Co., Ltd.
Publication of CY1119483T1 publication Critical patent/CY1119483T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Παρέχονται ένας παράγων για την αγωγή και/ή την προφύλαξη από μία αγχώδη διαταραχή ο οποίος περιλαμβάνει, ως δραστικό συστατικό, ένα παράγωγο του θειαζολίου που αναπαριστάται από τον τύπο (I) όπου το R1 αναπαριστά αρύλιο ή παρόμοιο, και το R2 αναπαριστά πυριδύλιο ή παρόμοιο, ή ένα φαρμακευτικά αποδεκτό άλας αυτού, και παρόμοια.
CY20171101029T 2009-09-02 2017-10-04 Θεραπευτικος παραγων για τις αγχωδεις διαταραχες CY1119483T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009202894 2009-09-02
PCT/JP2010/064989 WO2011027806A1 (ja) 2009-09-02 2010-09-02 不安障害治療剤

Publications (1)

Publication Number Publication Date
CY1119483T1 true CY1119483T1 (el) 2018-03-07

Family

ID=43649340

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101029T CY1119483T1 (el) 2009-09-02 2017-10-04 Θεραπευτικος παραγων για τις αγχωδεις διαταραχες

Country Status (31)

Country Link
US (1) US20120172362A1 (el)
EP (1) EP2474544B1 (el)
JP (1) JP5663485B2 (el)
KR (2) KR20170044768A (el)
CN (1) CN102482271A (el)
AU (1) AU2010290424C1 (el)
BR (1) BR112012004850A2 (el)
CA (1) CA2772922C (el)
CL (1) CL2012000533A1 (el)
CY (1) CY1119483T1 (el)
DK (1) DK2474544T3 (el)
DO (1) DOP2012000056A (el)
EA (1) EA023728B1 (el)
ES (1) ES2643840T3 (el)
GE (1) GEP20156225B (el)
HR (1) HRP20171418T1 (el)
HU (1) HUE036543T2 (el)
IL (1) IL218320A (el)
LT (1) LT2474544T (el)
MA (1) MA33619B1 (el)
ME (1) ME02877B (el)
MX (1) MX2012002529A (el)
NZ (1) NZ598754A (el)
PL (1) PL2474544T3 (el)
PT (1) PT2474544T (el)
RS (1) RS56401B1 (el)
SI (1) SI2474544T1 (el)
TN (1) TN2012000093A1 (el)
UA (1) UA113383C2 (el)
WO (1) WO2011027806A1 (el)
ZA (1) ZA201202347B (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE025659T2 (en) * 2003-12-26 2016-04-28 Kyowa Hakko Kirin Co Ltd Thiazole derivatives
MA41090A (fr) * 2014-12-03 2017-10-10 H Lundbeck As Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson
JOP20200093A1 (ar) 2015-01-09 2017-06-16 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول
JO3544B1 (ar) * 2015-03-19 2020-07-05 Kyowa Kirin Co Ltd عامل علاجي للاختلال الوظيفي في الفص الجبهي
BR112021004999A2 (pt) 2018-09-17 2021-06-08 Yungjin Pharm. Co., Ltd. composto e método de inibição de cdk7 em um sujeito

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2116967C (en) 1992-07-08 2003-08-19 Fumio Suzuki Antidepressants
DE69834500T2 (de) 1997-09-05 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. Xanthinderivative zur behandlung von hirnischämie
US20040152659A1 (en) * 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
AU4431000A (en) * 1999-05-12 2000-12-05 Fujisawa Pharmaceutical Co., Ltd. Novel use
JP2005516891A (ja) 2001-09-13 2005-06-09 シェーリング　コーポレイション アデノシンＡ２ａレセプタアンタゴニストと抗鬱薬または抗不安薬との組合せ
US6620811B2 (en) 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
MXPA05013148A (es) * 2003-06-10 2006-03-17 Kyowa Hakko Kogyo Kk Un metodo de tratamiento de un trastorno de la ansiedad.
HUE025659T2 (en) * 2003-12-26 2016-04-28 Kyowa Hakko Kirin Co Ltd Thiazole derivatives
JPWO2006137527A1 (ja) * 2005-06-23 2009-01-22 協和発酵キリン株式会社 チアゾール誘導体
LT1921077T (lt) * 2005-08-02 2017-09-25 Kyowa Hakko Kirin Co., Ltd. Agentas, skirtas miego sutrikimo gydymui ir (arba) prevencijai
UA110097C2 (uk) * 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою

Also Published As

Publication number Publication date
ZA201202347B (en) 2015-11-25
CA2772922A1 (en) 2011-10-03
KR20170044768A (ko) 2017-04-25
EA023728B1 (ru) 2016-07-29
AU2010290424C1 (en) 2016-02-18
WO2011027806A1 (ja) 2011-03-10
EP2474544B1 (en) 2017-07-12
KR20120047311A (ko) 2012-05-11
EP2474544A4 (en) 2013-01-23
UA113383C2 (xx) 2017-01-25
BR112012004850A2 (pt) 2020-06-23
MX2012002529A (es) 2012-04-11
DK2474544T3 (en) 2017-10-02
CL2012000533A1 (es) 2012-09-14
IL218320A0 (en) 2012-04-30
ES2643840T3 (es) 2017-11-24
CN102482271A (zh) 2012-05-30
PT2474544T (pt) 2017-10-03
HUE036543T2 (hu) 2018-07-30
GEP20156225B (en) 2015-01-26
JP5663485B2 (ja) 2015-02-04
MA33619B1 (fr) 2012-09-01
ME02877B (me) 2018-04-20
AU2010290424B2 (en) 2015-11-05
CA2772922C (en) 2017-11-21
EA201270360A1 (ru) 2012-09-28
EP2474544A1 (en) 2012-07-11
DOP2012000056A (es) 2012-06-30
RS56401B1 (sr) 2018-01-31
LT2474544T (lt) 2017-10-25
NZ598754A (en) 2014-08-29
US20120172362A1 (en) 2012-07-05
HRP20171418T1 (hr) 2017-11-03
PL2474544T3 (pl) 2017-12-29
JPWO2011027806A1 (ja) 2013-02-04
AU2010290424A1 (en) 2012-04-19
SI2474544T1 (sl) 2017-11-30
IL218320A (en) 2016-06-30
TN2012000093A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
CY1119118T1 (el) Θεραπευτικος παραγων για τις διαταραχες της διαθεσης
CY1119483T1 (el) Θεραπευτικος παραγων για τις αγχωδεις διαταραχες
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
CY1119488T1 (el) Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
CY1122805T1 (el) Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων
EA201591612A1 (ru) ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
CO6480927A2 (es) Derivados de imidazolin-2-ona 1,3-disustituida como inhibidores de cyp17.
EA201170872A1 (ru) Ингибиторы протеинкиназы
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
MX2020011652A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
NZ626112A (en) Triazinone compound and t-type calcium channel inhibitor
CY1124836T1 (el) Πυριδυλο-υδραζονες για τη θεραπεια της φυματιωσης και σχετικων ασθενειων
MX2012012410A (es) Agente terapeutico y agente preventivo para enfermedad de alzheimer.
EA201600411A1 (ru) Производные пиперидина для применения при лечении или профилактики психиатрических и неврологических состояний
CY1121690T1 (el) Κινολυλο-υδραζονες για την θεραπεια της φυματιωσης και σχετικων ασθενειων
PL400584A1 (pl) Zastosowanie medyczne 3-(tiofen-2-ylo)-1,2,4-triazolo-5-tionu
CY1114207T1 (el) Παραγωγα βενζοφουρανυλιου για χρηση ως αναστολεις γλυκοκινασης